InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
harr449 Free
08/24/22 12:32 PM
profile icon
Invest83838 Free
08/18/22 7:45 PM
profile icon
smul Free
08/18/22 2:50 PM
profile icon
irv12 Free
07/15/22 2:58 PM
profile icon
novicetrader Free
07/11/22 9:25 PM
profile icon
irv12 Free
07/11/22 10:03 AM
profile icon
novicetrader Free
07/07/22 10:59 AM
profile icon
irv12 Free
07/07/22 9:29 AM
profile icon
food4thought Free
05/20/22 1:32 PM
profile icon
smul Free
05/20/22 12:22 PM
profile icon
harr449 Free
11/08/21 4:53 PM
profile icon
harr449 Free
11/08/21 9:46 AM
profile icon
mik1234 Free
10/22/21 10:49 PM
profile icon
harr449 Free
10/06/21 10:50 AM
profile icon
harr449 Free
10/05/21 5:29 PM
profile icon
harr449 Free
09/29/21 5:48 PM
profile icon
harr449 Free
09/29/21 11:51 AM
profile icon
LINK Oracle Free
09/27/21 2:05 PM
profile icon
Invest83838 Free
09/27/21 8:45 AM
profile icon
TheFinalCD PremiumMember
09/27/21 8:41 AM
profile icon
Invest83838 Free
09/22/21 6:37 AM
profile icon
harr449 Free
09/21/21 4:11 PM
profile icon
Invest83838 Free
09/21/21 3:41 PM
profile icon
TheFinalCD PremiumMember
09/21/21 2:10 PM
profile icon
TheFinalCD PremiumMember
09/21/21 1:10 PM
profile icon
harr449 Free
09/14/21 2:06 PM
profile icon
Invest83838 Free
09/13/21 7:39 PM
profile icon
Invest83838 Free
09/13/21 7:32 PM

Seelos Therapeutics Inc (SEEL) RSS Feed

Followers
242
Posters
802
Posts (Today)
0
Posts (Total)
30352
Created
09/14/05
Type
Free
Moderators
Seelos Therapeutics, Inc.:
https://seelostherapeutics.com/

Seelos Therapeutics, Inc.
300 Park Avenue
New York, NY 10022


SEC Filings: https://seelostherapeutics.com/sec-filings/


Press Releases:
 https://seelostherapeutics.com/press-releases-2/

FOCUS:
Addressing unmet needs in neurological diseases and disorders and in rare diseases
Advancing multiple late-stage therapeutic candidates for CNS disorders
Developing therapeutics with proven mechanisms of action
Identifying opportunities in large markets

Seelos Therapeutics is exploring new ways to think about and treat central nervous system (CNS) disorders in neurological diseases and disorders and in rare diseases. Our trials are designed to further evaluate the safety and efficacy of our acquired assets. These come to Seelos with well characterized efficacy and safety, thereby avoiding much of the lengthy and burdensome process of preclinical R&D.

By working with clinically ready novel and reformulated compounds we will move from asset acquisition to meaningful data readouts in an expedited and efficient fashion. It is our goal to develop unique and disruptive therapies and approaches to improve treatment of large known diseases, offer new treatments for large unmet or recently characterized indications as well as advance therapies for orphan indications.

Our approach to this process will require development that is appropriate and efficient for a company our size in the scope of work each program requires in regards to trial size and duration.

We invite you to stay update on the progress of our assets in our clinical development programs.



Our Seelos Therapeutics Pipeline (as of May 2020)


Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
New Post